Ocular Features of Fabry Disease: Diagnosis of a Treatable Life-threatening Disorder

Survey of Ophthalmology

Volumn 53, Issue 4, 2008, Pages 416-423

  Samiy, Nasi ^a  

^a Retina Institute of the Carolinas   (United States)

Author keywords

cornea verticillata; Fabry disease; lens opacities; lysosomal enzyme

Indexed keywords

AMIODARONE; AMODIAQUINE; ATOVAQUONE; CHLOROQUINE; CLOFAZIMINE; GENTAMICIN; GOLD; IBUPROFEN; INDOMETACIN; MEPACRINE; MONOBENZONE; NAPROXEN; PERHEXILINE MALEATE; PHENOTHIAZINE; SURAMIN; TAMOXIFEN; TILORONE;

CATARACT; CLINICAL FEATURE; CONJUNCTIVA; CORNEA OPACITY; ENZYME REPLACEMENT; EYE EXAMINATION; FABRY DISEASE; HUMAN; LONG TERM CARE; MORBIDITY; MORTALITY; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVIEW; SCREENING; SEX DIFFERENCE; SLIT LAMP; VISION;

EYE DISEASES; FABRY DISEASE; HUMANS;

EID: 45249098702     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.survophthal.2008.04.005     Document Type: Review

References (48)

1. Andersen M.V., Dahl H., Fledelius H., et al. Central retinal artery occlusion in a patient with Fabry's disease documented by scanning laser ophthalmoscopy. Acta Ophthalmol (Copenh) 72 (1994) 635-638
2. Banikazemi M., Bultas J., Waldek S., et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146 (2007) 77-86
3. Banikazemi M., Ullman T., and Desnick R.J. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy. Mol Genet Metab 85 (2005) 255-259
4. Branton M.H., Schiffmann R., Sabnis S.G., et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 81 (2002) 122-138
5. Breunig F., Weidemann F., Strotmann J., et al. Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 69 (2006) 1216-1221
6. Chong E.M., Campbell R.J., and Bourne W.M. Vortex keratopathy in a patient with multiple myeloma. Cornea 16 (1997) 592-594
7. Dantas M.A., Fonseca R.A., Kaga T., et al. Retinal and choroidal vascular changes in heterozygous Fabry disease. Retina 21 (2001) 87-89
8. De Schoenmakere G., and Chauveau D. Grünfeld JP: Enzyme replacement therapy in Anderson-Fabry's disease: beneficial clinical effect on vital organ function. Nephrol Dial Transplant 18 (2003) 33-35
9. Desnick R.J., Brady R., Barranger J., et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138 (2003) 338-346
10. Desnick R.J., Ioannou Y.A., and Eng C.M. Alpha-galactosidase A deficiency: Fabry disease. In: Scriver C., Beaudet A., Sly W., et al. (Eds). Metabolic and Molecular Bases of Inherited Disease (2001), McGraw Hill, New York 3733-3734
11. Elleder M., Poupětová H., and Kozich V. [Fetal pathology in Fabry's disease and mucopolysaccharidosis type I]. Cesk Patol 34 (1998) 7-12
12. Eng C.M., Banikazemi M., Gordon R.E., et al. A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68 (2001) 711-722
13. Eng C.M., Fletcher J., Wilcox W.R., et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 30 (2007) 184-192
14. Eng C.M., Guffon N., Wilcox W.R., et al. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 345 (2001) 9-16
15. Font R.L., and Fine B.S. Ocular pathology in fabry's disease. Histochemical and electron microscopic observations. Am J Ophthalmol 73 (1972) 419-430
16. Franceschetti A.T. Fabry disease: ocular manifestations. Birth Defects Orig Artic Ser 12 (1976) 195-208
17. Galanos J., Nicholls K., Grigg L., et al. Clinical features of Fabry's disease in Australian patients. Intern Med J 32 (2002) 575-584
18. Guffon N., and Fouilhoux A. Clinical benefit in Fabry patients given enzyme replacement therapy-a case series. J Inherit Metab Dis 27 (2004) 221-227
19. Hauser A.C., Lorenz M., Voigtländer T., et al. Results of an ophthalmologic screening programme for identification of cases with Anderson-Fabry disease. Ophthalmologica 218 (2004) 207-209
20. Hirano K., Murata K., Miyagawa A., et al. Histopathologic findings of cornea verticillata in a woman heterozygous for Fabry's disease. Cornea 20 (2001) 233-236
21. Hollander D.A., and Aldave A.J. Drug-induced corneal complications. Curr Opin Ophthalmol 15 (2004) 541-548
22. Kopp J.B., and Schiffmann R. Images in clinical medicine. Fabry's disease. N Engl J Med 349:e20 (2003)
23. MacDermot K.D., Holmes A., and Miners A.H. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38 (2001) 750-760
24. MacDermot K.D., Holmes A., and Miners A.H. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38 (2001) 769-775
25. Macrae W.G., and Ghosh M. McCulloch C: Corneal changes in Fabry's disease: a clinico-pathologic case report of a heterozygote. Ophthalmic Paediatr Genet 5 (1985) 185-190
26. Meikle P.J., Hopwood J.J., Clague A.E., et al. Prevalence of lysosomal storage disorders. JAMA 281 (1999) 249-254
27. Moore D.F., Altarescu G., Herscovitch P., et al. Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease. BMC Neurol 2 (2002) 4
28. Moore D.F., Altarescu G., Ling G.S., et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 33 (2002) 525-531
29. Moore D.F., Scott L.T., Gladwin M.T., et al. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 104 (2001) 1506-1512
30. Morgan S.H., and Crawfurd M.A. Anderson-Fabry disease. BMJ 297 (1988) 872-873
31. Nguyen T.T., Gin T., Nicholls K., et al. Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre. Clin Experiment Ophthalmol 33 (2005) 164-168
32. Orssaud C., Dufier J., and Germain D. Ocular manifestations in Fabry disease: a survey of 32 hemizygous male patients. Ophthalmic Genet 24 (2003) 129-139
33. Oto S., Kart H., Kadayifçilar S., et al. Retinal vein occlusion in a woman with heterozygous Fabry's disease. Eur J Ophthalmol 8 (1998) 265-267
34. Ries M., Moore D.F., Robinson C.J., et al. Quantitative dysmorphology assessment in Fabry disease. Genet Med 8 (2006) 96-101
35. Ries M., Ramaswami U., Parini R., et al. The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr 162 (2003) 767-772
36. Rolfs A., Böttcher T., Zschiesche M., et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 366 (2005) 1794-1796
37. Schiffmann R., Floeter M.K., Dambrosia J.M., et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 28 (2003) 703-710
38. Schiffmann R., Kopp J.B., Austin H.A., et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285 (2001) 2743-2749
39. Sher N.A., Letson R.D., and Desnick R.J. The ocular manifestations in Fabry's disease. Arch Ophthalmol 97 (1979) 671-676
40. Sher N.A., Reiff W., Letson R.D., et al. Central retinal artery occlusion complicating Fabry's disease. Arch Ophthalmol 96 (1978) 815-817
41. Sodi A., Ioannidis A.S., Mehta A., et al. Ocular manifestations of Fabry's disease: data from the Fabry Outcome Survey. Br J Ophthalmol 91 (2007) 210-214
42. Spaeth G.L., and Frost P. Fabrys disease. Its ocular manifestations. Arch Ophthalmol 74 (1965) 760-769
43. Tsutsumi A., Uchida Y., Kanai T., et al. Corneal findings in a foetus with Fabry's disease. Acta Ophthalmol (Copenh) 62 (1984) 923-931
44. Vedder A.C., Linthorst G.E., van Breemen M.J., et al. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 30 (2007) 68-78
45. Whybra C., Kampmann C., Willers I., et al. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 24 (2001) 715-724
46. Wilcox W.R. Lysosomal storage disorders: the need for better pediatric recognition and comprehensive care. J Pediatr 144 (2004) S3-S14
47. Wilcox W.R., Banikazemi M., Guffon N., et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75 (2004) 65-74
48. Witschel H., and Mathyl J. [Morphological bases of the specific ocular changes in Fabry's disease]. Klin Monatsbl Augenheilkd 154 (1969) 599-605